Notice of Clarification of Responsiveness to NIAAA RFA-AA-21-004 "SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed)"
Notice Number:
NOT-AA-21-041

Key Dates

Release Date:

July 14, 2021

Related Announcements

RFA-AA-21-004 - SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed)

Issued by

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Purpose

This Notice provides clarifying information on responsiveness for Funding Opportunity Announcement (FOA) RFA-AA-21-004. Applications submitted to RFA-AA-21-004 will be accepted for review only if they propose research that is genuinely time-sensitive. It is the responsibility of investigators to clearly state in the Significance section of the application why the research needs a substantially shorter turnaround than the usual NIH grant review/award cycle and what will be lost if the onset is delayed. It should be clear that the COVID-19 pandemic offers a limited opportunity to address unique and important research questions that could only be answered if the project is initiated with minimum delay. Investigators should describe their capacity to begin the project upon award. Applications lacking a credible justification in the Significance section will not be considered responsive to this RFA and will be withdrawn.

Inquiries

Please direct all inquiries to:

M. Kathy Jung. Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
301-443-8744
Email: jungma@mail.nih.gov

Changhai Cui, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
301-443-1678
Email: changhai.cui@nih.gov

Gregory Bloss, M.A., M.P.P.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
301-443-3865
Email: gregory.bloss@nih.gov

Laura Kwako, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
301-451-8507
Email: laura.kwako@nih.gov


Weekly TOC for this Announcement
NIH Funding Opportunities and Notices